GP方案治疗中晚期非小细胞肺癌的疗效观察  

The efficacy and toxicity of gemcitabine plus cisplatin in the treatment of advanced non-small cell lung cancer

作　　者：倪秉洁[1] 

机构地区：[1]辽宁省肿瘤医院内一科,沈阳110042

出　　处：《癌症进展》2005年第3期276-278,共3页Oncology Progress

摘　　要：目的　评价GP方案(健择+顺铂)对中晚期非小细胞肺癌(NSCLC)的疗效,临床受益反应和毒副作用。方法　5 4例中晚期非小细胞肺癌,初治35例,复治19例。以健择+顺铂方案化疗。每例持续2～4个周期,共14 6个周期。结果　5 4例化疗患者,有效率达4 4 4 % ,稳定(SD)者占37% ,进展(PD)者占18 5 %。毒副反应:Ⅲ～Ⅳ度白细胞减少者为31 4 % ,Ⅲ～Ⅳ度血小板减少者为4 0 7% ,Ⅲ～Ⅳ度血红蛋白降低者为2 3 9% ,因毒副反应而周期内延期2 7次(18 5 % ) ,但不影响化疗方案进行。结论　健择联合顺铂治疗中晚期非小细胞肺癌有较好疗效,它的毒副反应轻,易耐受,可明显改善患者生存质量,延长生存时间。Objective To observe the efficacy and toxicity of gemcitabine plus cisplatin in the treatment of advanced non-small cell lung cancer(NSCLC).Methods Among 54 NSCLC cases,35 patients were untreated tumors cases,19 were recurrent tumors cases.They were all treated by gemcitabine plus cisplatin.Results The response rate(CR+PR)was 44.4%,SD 12(37%),PD 7(18.5%).The main toxicity was hematological:Cycles of hemolaobin,neutropenia and platelete of WHO grade Ⅲ-Ⅳwere 25.9%,40.7%,31.4% respectively.The non-hematological toxicity was mild and tolerable.Among 146 cycles,only 27 cycles(18.5%)gemcitabine injection were prolonged due to toxicity.Conclusion The regimen of gemcitabine in combination with cisplatin is effective,safe and well-tolerance in the treatment of NSCLC.It significantly improve the quality of life in patients with NSCLC,prolonging the survival time.

关 键 词：非小细胞肺癌 化疗 健择 顺铂 

分 类 号：R730.53[医药卫生—肿瘤]